GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 5, 2014, Pages

  Ye, Jianping ^a   Hao, Zheng ^a   Mumphrey, Michael B ^a   Leigh Townsend, R ^a   Patterson, Laurel M ^a   Stylopoulos, Nicholas ^b   Münzberg, Heike ^a   Morrison, Christopher D ^a   Drucker, Daniel J ^c   Berthoud, Hans Rudolf ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

BIIE0246; Brain; Exendin (9 39); Food intake; GLP 1R knockout; Gut hormones; High fat diet; Roux en Y gastric bypass

Indexed keywords

EXENDIN 9; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ARGININE; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; EXENDIN (9 39); EXENDIN (9-39); GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARIATRIC SURGERY; BODY WEIGHT; BRAIN; CONTROLLED STUDY; DRUG INFUSION; FAT MASS; FOOD INTAKE; LATERAL BRAIN VENTRICLE; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; ROUX Y ANASTOMOSIS; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; BODY COMPOSITION; DRUG ANTAGONISM; DRUG EFFECT; EATING; ENERGY METABOLISM; EXENDIN-(9-39), BIIE0246; FAT INTAKE; GENETICS; GLP-1R KNOCKOUT; GUT HORMONES; HIGH-FAT DIET; KNOCKOUT MOUSE; METABOLISM; MOTOR ACTIVITY; MOUSE; OXYGEN CONSUMPTION; PHYSIOLOGY; ROUX-EN-Y GASTRIC BYPASS; SPRAGUE DAWLEY RAT; STOMACH BYPASS;

BRAIN; EXENDIN-(9-39), BIIE0246; FOOD INTAKE; GLP-1R KNOCKOUT; GUT HORMONES; HIGH-FAT DIET; ROUX-EN-Y GASTRIC BYPASS;

ANIMALS; ARGININE; BENZAZEPINES; BODY COMPOSITION; BODY WEIGHT; DIETARY FATS; EATING; ENERGY METABOLISM; GASTRIC BYPASS; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; OBESITY; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84899431728     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00491.2013     Document Type: Article

References (65)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131, 2005.
2. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA, Bloom SR. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043: 139-144, 2005.
3. Abegg K, Schiesser M, Lutz TA, Bueter M. Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass. Physiol Behav 121: 70-78, 2013.
4. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153: 647-658, 2012.
5. Baraboi ED, Michel C, Smith P, Thibaudeau K, Ferguson AV, Richard D. Effects of albumin-conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerve. Eur J Neurosci 32: 826-839, 2010.
6. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31: 3904-3913, 2011.
7. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 7: 507-516, 2011.
8. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654, 2002.
9. Batterham RL, Fytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450: 106-109, 2007.
10. Berthoud HR, Shin AC, Zheng H. Obesity surgery and gut-brain communication. Physiol Behav 105: 106-119, 2011.
11. Brothers SP, Saldanha SA, Spicer TP, Cameron M, Mercer BA, Chase P, McDonald P, Wahlestedt C, Hodder PS. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol Pharmacol 77: 46-57, 2010.
12. Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 151: 1984-1989, 2010.
13. Chambers AP, Jessen L, Ryan KK, Sisley S, Wilson-Perez HE, Stefater MA, Gaitonde SG, Sorrell JE, Toure M, Berger J, D'Alessio DA, Woods SC, Seeley RJ, Sandoval DA. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 141: 950-958, 2011.
14. Chandarana K, Gelegen C, Karra E, Choudhury AI, Drew ME, Fauveau V, Viollet B, Andreelli F, Withers DJ, Batterham RL. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 60: 810-818, 2011.
15. Chelikani PK, Haver AC, Reeve JR Jr, Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 290: R298-R305, 2006.
16. Chelikani PK, Shah IH, Taqi E, Sigalet DL, Koopmans HH. Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats. Obes Surg 20: 1281-1288, 2010.
17. Dailey MJ, Moghadam AA, Moran TH. Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab 301: E1184-E1190, 2011.
18. Dar MS, Chapman WH, 3rd Pender JR, Drake AJ, 3rd O'Brien K, Tanenberg RJ, Dohm GL, Pories WJ. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg 22: 1077-1083, 2012.
19. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD, Dhillo WS. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 14: 700-706, 2011.
20. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32: 4812-4820, 2012.
21. Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 31: 14453-14457, 2011.
22. Fenske WK, Bueter M, Miras AD, Ghatei MA, Bloom SR, le Roux CW. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Int J Obes (Lond) 36: 379-384, 2012.
23. Guan X, Shi X, Li X, Chang B, Wang Y, Li D, Chan L. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. Am J Physiol Endocrinol Metab 303: E853-E864, 2012.
24. Habegger KM, Heppner KM, Amburgy SE, Ottaway N, Holland J, Raver C, Bartley E, Muller TD, Pfluger PT, Berger J, Toure M, Benoit SC, Dimarchi RD, Perez-Tilve D, D'Alessio DA, Seeley RJ, Tschop MH. GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. Diabetes In press.
25. Hao Z, Zhao Z, Berthoud HR, Ye J. Development and verification of a mouse model for Roux-en-Y gastric bypass surgery with a small gastric pouch. PLoS One 8: e52922, 2013.
26. Hassan M, Eskilsson A, Nilsson C, Jonsson C, Jacobsson H, Refai E, Larsson S, Efendic S. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol 26: 413-420, 1999.
27. Hayes MR, Bradley L, Grill HJ. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150: 2654-2659, 2009.
28. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152: 3103-3112, 2011.
29. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18: 7-14, 2002.
30. Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 167: 355-360, 2013.
31. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Penicaud L, Valet P, Burcelin R. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149: 4768-4777, 2008.
32. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3: 597-601, 2007.
33. Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B, Bessler M. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 33: 786-795, 2009.
34. Kunnecke B, Verry P, Benardeau A, von Kienlin M. Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry. Obes Res 12: 1604-1615, 2004.
35. Labouesse MA, Stadlbauer U, Weber E, Arnold M, Langhans W, Pacheco-Lopez G. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocrinol 24: 1505-1516, 2012.
36. Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30: 1709-1716, 2007.
37. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243: 108-114, 2006.
38. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H, Fandriks L, Ghatei MA, Bloom SR, Olbers T. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246: 780-785, 2007.
39. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 276: 21489-21499, 2001.
40. Ma X, Bruning J, Ashcroft FM. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 27: 7125-7129, 2007.
41. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96: 1569-1573, 1999.
42. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43, 2004.
43. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124: S3-S18, 2011.
44. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, Kern B, von Fluee M, Beglinger C. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 22: 740-748, 2012.
45. Pinilla L, Fernandez-Fernandez R, Roa J, Castellano JM, Tena-Sempere M, Aguilar E. Selective role of neuropeptide Y receptor subtype Y2 in the control of gonadotropin secretion in the rat. Am J Physiol Endocrinol Metab 293: E1385-E1392, 2007.
46. Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Vilsboll T, Knop FK, Holst JJ. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 304: G1117-G1127, 2013.
47. Pournaras DJ, Osborne A, Hawkins SC, Mahon D, Ghatei MA, Bloom SR, Welbourn R, le Roux CW. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg 20: 56-60, 2010.
48. Redman LM, Heilbronn LK, Martin CK, de Jonge L, Williamson DA, Delany JP, Ravussin E. Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss. PLoS One 4: e4377, 2009.
49. Reidelberger R, Haver A, Chelikani PK. Role of peptide YY(3-36) in the satiety produced by gastric delivery of macronutrients in rats. Am J Physiol Endocrinol Metab 304: E944-E950, 2013.
50. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 16: 298-305, 2008.
51. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 1174-1181, 2009.
52. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate GLP-1 receptors regulate glucose homeostasis but not food intake. Diabetes 57: 2046-2054, 2008.
53. Scott V, Kimura N, Stark JA, Luckman SM. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 17: 452-457, 2005.
54. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
55. Seeley RJ, Moran TH. Principles for interpreting interactions among the multiple systems that influence food intake. Am J Physiol Regul Integr Comp Physiol 283: R46-R53, 2002.
56. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Mealinduced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 151: 1588-1597, 2010.
57. Stadlbauer U, Arnold M, Weber E, Langhans W. Possible mechanisms of circulating PYY-induced satiation in male rats. Endocrinology 154: 193-204, 2013.
58. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756, 2005.
59. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 271: R848-R856, 1996.
60. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6: 802-807, 2000.
61. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25 Suppl 5: S42-S47, 2001.
62. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA. Glucagonlike peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 4965-4973, 2007.
63. Williams DL. Finding the sweet spot: peripheral versus central glucagonlike peptide 1 action in feeding and glucose homeostasis. Endocrinology 150: 2997-3001, 2009.
64. Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, Stoffers D, Drucker DJ, Perez-Tilve D, Seeley RJ. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide-1 receptor deficiency. Diabetes 62: 2380-2385, 2013.
65. Zheng H, Townsend RL, Shin AC, Patterson LM, Phifer CB, Berthoud HR. High-fat intake induced by mu-opioid activation of the nucleus accumbens is inhibited by Y1R-blockade and MC3/4R-stimulation. Brain Res 1350: 131-138, 2010.